Founded in 2005, Procyrion, Inc. has identified an opportunity in the sweet spot—the time between when the drugs start to fail and a last-resort surgical intervention—to treat millions of NYHA Class III-IVa heart failure patients using a novel and minimally invasive catheter-based heart pump, Aortix. This groundbreaking interventional cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, Medical Director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, was designed to reduce the workload of the failing heart, which allows the muscle a chance to rest and heal.
